Skip to content
The Policy VaultThe Policy Vault

caspofungin — CareFirst (Caremark)

Treatment of invasive aspergillosis in adult and pediatric patients (age ≥ 3 months) who are refractory to or intolerant of other therapies

Initial criteria

  • Patient meets FDA-approved indication for Cancidas: empirical therapy for presumed fungal infections in febrile, neutropenic patients, treatment of candidemia or specific Candida infections, esophageal candidiasis, or invasive aspergillosis in patients refractory to or intolerant of other therapies